UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM SD
SPECIALIZED DISCLOSURE REPORT
MERIDIAN BIOSCIENCE, INC.
(Exact name of the registrant as specified in its charter)



Ohio
0-14902
31-0888197
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)
     
     
3471 River Hills Drive,
Cincinnati, Ohio
 

45244
(Address of principal executive offices)
 
(Zip code)
     
     
 
Eric S. Rasmussen           (513) 271-3700
 
 
(Name and telephone number, including area code,
of the person to contact in connection with this report.)
 



Check the appropriate box to indicate the rule pursuant to which this form  is  being  filed, and  provide  the  period  to  which  the  information  in  this form applies:

  X    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2018.

___ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ___________________.





SECTION 1. CONFLICT MINERALS DISCLOSURE

Item 1.01     Conflict Minerals Disclosure and Report

Meridian Bioscience, Inc. ("Meridian" or the "Company") evaluated its products during the year ended December  31, 2018 and  determined  that  certain  products manufactured or contracted to be manufactured by the Company contain tin, tungsten, tantalum, and/or gold.  As a result, Meridian has filed a Conflict Minerals Report ("CMR"). A copy of Meridian's CMR is furnished as Exhibit 1.01 to this Form SD and is incorporated herein by reference. Copies of Meridian's Form SD and CMR are also available at the Meridian corporate website:  www.meridianbioscience.com .



SECTION 2. EXHIBITS

Item 2.01     Exhibits

Exhibit 1.01     Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Date:   May 23, 2019
MERIDIAN BIOSCIENCE, INC.
 
By: /s/ Eric S. Rasmussen                                                           
       Eric S. Rasmussen
       Executive Vice President and Chief Financial Officer

 


Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Meridian Bioscience Charts.
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Meridian Bioscience Charts.